BeiGene plans to open new manufacturing site and R&D center for the development of advanced new medicines.
The new state-of-the-art manufacturing site is laid in 42-acre site. The initial phase of the construction is designed with several hundred million dollars. Moreover, it has more than one million square feet of developable real estate for potential future expansion.
The establishment of this new facility will advance impactful treatments by making it more accessible to patients around the world. In addition, the medicines will be manufactured in the new facility.
This 400,000 square feet will be completely dedicated for commercial-stage biologic pharmaceutical manufacturing consisting of 16,000 liters of biologics capacity accompanied with clinical R&D and office space.
The construction of the manufcaturing facility is expected to start in 2022 and be completed in late-2023 or in 2024.